Plus Therapeutics, Inc. (NASDAQ:PSTV) Short Interest Update

Plus Therapeutics, Inc. (NASDAQ:PSTV) was the target of a large drop in short interest during the month of December. As of December 15th, there was short interest totalling 94,000 shares, a drop of 17.5% from the November 30th total of 114,000 shares. Based on an average daily trading volume, of 90,000 shares, the short-interest ratio is currently 1.0 days. Currently, 1.6% of the shares of the company are sold short.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Ascendiant Capital Markets lowered their target price on Plus Therapeutics from $20.00 to $19.00 and set a “buy” rating on the stock in a research note on Monday, December 9th. HC Wainwright restated a “buy” rating and issued a $8.00 price objective on shares of Plus Therapeutics in a research report on Tuesday, November 26th.

Institutional Trading of Plus Therapeutics

A hedge fund recently bought a new stake in Plus Therapeutics stock. AIGH Capital Management LLC purchased a new stake in Plus Therapeutics, Inc. (NASDAQ:PSTV) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 568,681 shares of the company’s stock, valued at approximately $836,000. AIGH Capital Management LLC owned 9.98% of Plus Therapeutics as of its most recent filing with the SEC. Institutional investors and hedge funds own 3.28% of the company’s stock.

Plus Therapeutics Stock Performance

Shares of PSTV stock remained flat at $1.15 during mid-day trading on Tuesday. 40,123 shares of the stock traded hands, compared to its average volume of 63,673. Plus Therapeutics has a twelve month low of $0.93 and a twelve month high of $2.67. The company has a market capitalization of $6.78 million, a P/E ratio of -0.45 and a beta of 0.70. The stock’s 50-day moving average price is $1.26 and its two-hundred day moving average price is $1.46.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.